Edigene

Developer of genome editing technology for the treatment of cancer and genetic disease

placeChangping District, Beijing, China calendar_todayFounded 2015 groups140 employees language edigene.com

Innovation

22 patent families (2 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 838 times.

YearFilings
20182
20197
20207
202115
20228
20235
20242

Investor mix

18 investors on record; lead investors include Loayal Valley Capital, IDG Capital, Lilly Asia Ventures, Huagai Capital.

Investor typeCountShare
Venture capital950%
Private equity633%
Other / undisclosed317%
Coming soon